Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Self-Reported Dietary Habits, Overall Dietary Quality and Symptomatology of Breast Cancer Survivors: a Cross-Sectional Examination
Authors
C.C. Tangney
J.A. Young
M.A. Murtaugh
M.A. Cobleigh
D.M. Oleske
Publication date
01-01-2002
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2002
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1013885508755

Other articles of this Issue 2/2002

Breast Cancer Research and Treatment 2/2002 Go to the issue

Conference Report

Minor Role for BRCA2 (Exon11) and p53 (Exon 5–9) Among Sudanese Breast Cancer Patients

Conference Report

In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells

Conference Report

Breast and Ovarian Cancer Screening Practices in Healthy Women with a Strong Family History of Breast or Ovarian Cancer

Conference Report

Prognostic Significance of Tumor Cell Proliferation Analyzed in Fine Needle Aspirates from Primary Breast Cancer

Conference Report

Irofulven Induces Apoptosis in Breast Cancer Cells Regardless of Caspase-3 Status*

Conference Report

Tamoxifen-Induced Increases in Cytoplasmic Free Ca2+ Levels in Human Breast Cancer Cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits